Hypothesis Introduces First Skincare Line to Achieve MyMicrobiome’s New Eczema Certification

The certification highlights that Hypothesis™ products are scientifically validated to reduce Staphylococcus aureus bacteria, crucial for microbiome-safe eczema care, thanks to TPZ-01™, an enzyme that targets this bacteria without harming the skin’s microbiome. Oliver Liu, Ph.D., co-founder of Hypothesis™ and Topaz Biosciences, emphasizes the innovation of directly targeting Staph aureus. The Hypothesis™ collection includes a hydrogel, spray, and therapy cream, available at www.hypothesis.bio from September 30. Moreover, in July 2025, MyMicrobiome introduced new skincare standards for eczema-prone skin.